Where to get your overview of Social Media in Pharma? Right here: http://bit.ly/socialrx
Pharma’s new hot properties – vaccines.
Boehringer Ingelheim pressing forward with its experimental DPP-4 inhibitor for diabetes – Boehringer Ingelheim Pharmaceuticals, Inc. today announced the conclusion of the linagliptin pivotal Phase III clinical trials, including more than 4,000 patients in 40 countries worldwide. Phase II data for linagliptin were presented earlier this year at the annual American Diabetes Association (ADA) Scientific Sessions. Full results from the Phase III trials will be presented at international scientific congresses in 2010 and beyond...more
Merck’s diabetes drug Januvia significantly lowers blood sugar – A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia®’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years…more
Product/Launch training. The Impactiviti Partner Network has great providers to help you develop your new product training – print, on-line, and live. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Has the game changed in a dramatic way in pharma social media? I think it may be likely – my initial thoughts on Google’s Sidewiki tool, which allows user commentary on ANY site.
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Connect with Steve Woodruff